Gold prices steady ahead of Fed decision, Trump’s tariff deadline
LONDON - Hikma Pharmaceuticals (OTC:HKMPY) PLC (LSE:HIK) will release its interim financial results for the six months ended June 30, 2025, on Thursday, August 7, 2025, according to a company statement issued Wednesday.
The pharmaceutical company will make a presentation recording available on its corporate website from 7:00 AM BST on the day of the announcement. A live question-and-answer conference call for analysts will follow at 9:00 AM BST, with a recording to be posted on the company website afterward.
Investors and analysts wishing to participate in the conference call can dial in using several provided contact numbers, including the United Kingdom (TADAWUL:4280) local number (+44 20 3936 2999) or toll-free number (+44 808 189 0158), using access code 358168.
Hikma Pharmaceuticals, headquartered in the UK, produces branded and non-branded generic medicines. The company operates across North America, the Middle East, North Africa, and Europe, employing approximately 9,500 people globally.
The company is listed on the London Stock Exchange (LON:LSEG) and NASDAQ Dubai, and is rated BBB/stable by both S&P and Fitch.
This announcement was made through a press release statement distributed via the Regulatory News Service (RNS) of the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.